The positive Phase 1 safety and PK data de-risk ACI-19764 and confirm CNS penetration, a key differentiator among NLRP3 inhibitors. Traders should focus on the upcoming hsCRP data from the cardiovascular cohort, expected by year-end 2026, as a potential catalyst for anti-inflammatory proof-of-mechanism. If positive, this could significantly increase the program's value and partnership prospects.
Price Chart
Executive Summary
AC Immune announced positive preliminary Phase 1 data for its wholly-owned NLRP3 inhibitor ACI-19764, showing safety, tolerability, and CSF penetration in healthy volunteers. The therapeutic dose is expected to be 10mg once daily, and a cardiovascular risk cohort is now dosing with initial hsCRP results expected by year-end. Full Phase 1/1b results are anticipated in H1 2027.
Key Facts
- Preliminary Phase 1 data showed ACI-19764 was safe and well-tolerated across SAD and MAD cohorts, with no serious adverse events and no treatment withdrawals.
- Clear CSF penetration (brain penetration) confirmed; daily doses of 10mg achieved PK concentrations above IC90.
- Serum half-life >30 hours; dose-dependent inhibition of IL-1beta release observed in whole blood assay.
- Therapeutic dose expected to be 10mg once daily based on PK data.
- Phase 1b cardiovascular risk cohort (elevated hsCRP + type 2 diabetes and/or obesity) now dosing; initial results expected by year-end 2026.
- Full Phase 1/1b trial results expected in H1 2027.
- ACI-19764 is wholly-owned by AC Immune; no partner or licensing revenue tied to this program mentioned.
Financial Impact
Early-stage pipeline value inflection; no revenue or financial data reported. The program is wholly-owned and could unlock substantial value if Phase 1b hsCRP data and subsequent trials are positive, but there are no dollar amounts disclosed.
Risk Factors
- Phase 1/1b data are early and from healthy volunteers, not patients; safety and efficacy in target populations remain unproven.
- No financial data, revenue, or guidance was provided — the filing is a pure pipeline update with binary outcome risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001651625-26-000018 |
| Document: aciu-20260820x6k.htm | 0001651625-26-000018 |
| Document: 0001651625-26-000018-index-headers.html | 0001651625-26-000018 |
| Document: 0001651625-26-000018-index.html | 0001651625-26-000018 |
| Document: 0001651625-26-000018.txt | 0001651625-26-000018 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.31 (−5.71%) |
Oct 9, 2026 17d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.31 (−7.60%) |
Oct 2, 2026 24d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.31 (−15.23%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.31 (−18.37%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.31 (−21.16%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.31 (−12.50%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.31 (−12.50%) |
Aug 11, 2026 10w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.31 (−9.06%) |
Aug 11, 2026 10w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.31 (−9.06%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.31 (+0.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers